$140 Million Verdict in AndroGel Testosterone Case
A federal jury in Chicago has ordered the pharmaceutical company AbbVie Inc. to pay a Tennessee man more than $140 million as compensation for a heart attack he claimed was caused by his taking testosterone-replacement drug AndroGel.
This premium content is reserved for Daily Business Review subscribers.
Continue reading by getting started with a subscription.
Already a subscriber? Log in now